Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cancer drug stop myeloma before it starts?

NCT ID NCT02316106

Completed Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested three different schedules of the drug daratumumab in 123 people with smoldering multiple myeloma, a condition that often progresses to active multiple myeloma. The goal was to see how well each schedule controlled the disease and led to complete responses. Researchers measured response rates and how many patients progressed or died.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

daratumumab

What this could lead to

If successful, this could help delay or prevent smoldering multiple myeloma from becoming active multiple myeloma, potentially reducing the need for more intensive treatments.

What could go wrong

This is a phase 2 trial with only 123 participants, so results are preliminary. Daratumumab may cause side effects like infusion reactions or infections, and not all patients may benefit.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Smoldering Multiple Myeloma smoldering plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

  • Study site

    Little Rock, Arkansas, United States

  • Study site

    Jacksonville, Florida, United States

  • Study site

    West Palm Beach, Florida, United States

  • Study site

    Atlanta, Georgia, United States

  • Study site

    Boston, Massachusetts, United States

  • Study site

    Ann Arbor, Michigan, United States

  • Study site

    St Louis, Missouri, United States

  • Study site

    Hackensack, New Jersey, United States

  • Study site

    New York, New York, United States

  • Study site

    Chapel Hill, North Carolina, United States

  • Study site

    Cincinnati, Ohio, United States

  • Study site

    Columbus, Ohio, United States

  • Study site

    Philadelphia, Pennsylvania, United States

  • Study site

    Nashville, Tennessee, United States

  • Study site

    Seattle, Washington, United States

  • Study site

    Box Hill, Australia

  • Study site

    Concord, Australia

  • Study site

    Melbourne, Australia

  • Study site

    Woodville South, Australia

  • Study site

    Calgary, Alberta, Canada

  • Study site

    Edmonton, Alberta, Canada

  • Study site

    Toronto, Ontario, Canada

  • Study site

    Brno, Czechia

  • Study site

    Hradec Králové, Czechia

  • Study site

    Prague, Czechia

  • Study site

    Lille, France

  • Study site

    Nantes, France

  • Study site

    Paris, France

  • Study site

    Pierre-Bénite, France

  • Study site

    Rennes, France

  • Study site

    Berlin, Germany

  • Study site

    Chemnitz, Germany

  • Study site

    Essen, Germany

  • Study site

    Heidelberg, Germany

  • Study site

    Mainz, Germany

  • Study site

    München, Germany

  • Study site

    Tübingen, Germany

  • Study site

    Würzburg, Germany

  • Study site

    Haifa, Israel

  • Study site

    Jerusalem, Israel

  • Study site

    Petah Tikva, Israel

  • Study site

    Tel Aviv, Israel

  • Study site

    Amsterdam, Netherlands

  • Study site

    Rotterdam, Netherlands

  • Study site

    Utrecht, Netherlands

  • Study site

    Nizhny Novgorod, Russia

  • Study site

    Petrozavodsk, Russia

  • Study site

    Ryazan, Russia

  • Study site

    Saint Petersburg, Russia

  • Study site

    Ankara, Turkey (Türkiye)

  • Study site

    Antalya, Turkey (Türkiye)

  • Study site

    Izmir, Turkey (Türkiye)

  • Study site

    Samsun, Turkey (Türkiye)

  • Study site

    Cardiff, United Kingdom

  • Study site

    Nottingham, United Kingdom

  • Study site

    Southampton, United Kingdom

  • Study site

    Surrey, United Kingdom